Queen's Award Received in 2021 ISO 9001 Certified Delivered over 1,000,000 bio-reagents to life science researchers Trusted by Life Science Communities
Cart summary

You have no items in your shopping cart.

TAS1553

SKU: orb1689776

Description

TAS1553 is a potent, orally bioavailable small molecule PPI inhibitor (IC50 = 39.6 nM) that disrupts DNA replication by depleting dATP, leading to apoptosis. It is a valuable research tool for investigating cancer therapeutics in both cellular and in vivo models.

Research Area

Cell Biology

Images & Validation

Key Properties

CAS Number2166023-31-8
MW482.91
Purity99.13% (May vary between batches)
FormulaC20H20ClFN4O5S
SMILESC[C@@H]([C@H](NS(=O)(=O)c1ccc(Cl)cc1C(N)=O)c1n[nH]c(=O)o1)c1c(F)ccc(C)c1C
TargetApoptosis,Others
SolubilityDMSO:90 mg/mL (186.37 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:3.3 mg/mL (6.83 mM)

Bioactivity

In Vivo
TAS1553, administered orally at doses ranging from 25-200 mg/kg for 24 hours, exhibits ribonucleotide reductase (RNR) inhibitory effects in female F344/NJcl-rnu/rnu rats and BALB/cAJcl-nu/nu mice, as evidenced by reduced intracellular dATP pools, induction of replication stress, and apoptosis . Further, when given daily at dosages of 50-200 mg/kg for 15 days, it demonstrates significant antitumor activity, with tumor growth inhibition rates in the treated versus control group being 52.0% at 50 mg/kg, 45.0% at 100 mg/kg, and 29.4% at 200 mg/kg, respectively . These findings underline the compound's potential in cancer therapeutics through both its inhibitory action on RNR and its capacity to reduce tumor growth effectively in vivo.
In Vitro
TAS1553, within a concentration range of 0.001-1 μM, inhibits the enzymatic activity of RNR dose-dependently. At a concentration administered for three days, TAS1553 exhibits anti-proliferative effects against various solid and hematological human cancer cell lines, with GI50 values spanning from 0.228 to 4.15 μM. In experiments involving HCC38 and MV-4-11 cells, TAS1553 (1-10 μM; over 0-2 hours) significantly decreases the intracellular dATP pool, essential for DNA replication, in both a dose- and time-dependent manner. Furthermore, at concentrations ranging from 0 to 10 μM and over a period of 0 to 24 hours, TAS1553 induces replication stress and apoptosis in HCC38 and MV-4-11 cells, showcasing a dependence on both dosage and time. Western Blot Analysis reveals that, across varying concentrations (0, 0.1, 0.3, 1, 3, and 10 μM) and incubation times (0, 1, 2, 4, 8, and 24 hours), there is an increase in the phosphorylation of Ser345, Ser4, Ser8, and Thr21. Additionally, these conditions result in the increased levels of cleaved PARP and cleaved caspase-3, signaling enhanced apoptosis in the tested cell lines.

Storage & Handling

Storage-20°C
Expiration Date12 months from date of receipt.
DisclaimerFor research use only

Alternative Names

TAS 1553, TAS1553, TAS-1553, protein–protein interaction (PPI)
Quality Guarantee

Quality Guarantee

Explore bioreagents carefree to elevate your research. All our products are rigorously tested for performance. If a product does not perform as described on its datasheet, our scientific support team will provide expert troubleshooting, a prompt replacement, or a refund. For full details, please see our Terms & Conditions and Buying Guide. Contact us at [email protected].

Key Properties

No computed properties available.

Protocol Information

Available Sizes

Select a size below

1 mg
$ 90.00
5 mg
$ 160.00
1 ml x 10 mM (in DMSO)
$ 170.00
10 mg
$ 230.00
25 mg
$ 420.00
50 mg
$ 560.00
100 mg
$ 760.00
DispatchUsually dispatched within 5-10 working days
Bulk Enquiry